THE POWER OF PARTNERSHIPS

2017 ANNUAL IMPACT REPORT
When two hours’ sleep is a good night. When staying alive is a 24-hour-a-day job. When having an increased risk of serious long-term complications is just part of your reality. This is life with type 1 diabetes (T1D).

But by working together, we’re getting closer than ever to finding lasting treatments and a cure.

Through the power of partnerships we will change the future for people living with T1D.

About JDRF Canada
Founded over 40 years ago, JDRF Canada is one of seven JDRF affiliates worldwide. The leading global organization funding T1D research, JDRF has a goal to progressively remove the impact of T1D from people’s lives until we achieve a world without this disease. JDRF collaborates with a wide spectrum of partners and is the only organization with the scientific resources, regulatory influence, and a working plan to better treat, prevent, and eventually cure T1D.

CONTENTS
1 LEADERSHIP MESSAGE
3 RESEARCH UPDATE
12 GOVERNMENT RELATIONS AND ADVOCACY
14 IN OUR LIFETIME CAMPAIGN
16 MEET OUR VOLUNTEERS
17 JDRF IN THE COMMUNITY
19 OUR EVENTS
24 OUR NATIONAL PARTNERS
25 2017 BOARD OF DIRECTORS
LEADERSHIP MESSAGE

The power of partnerships has always been one of JDRF’s greatest strengths.

For over 40 years, we have brought together diverse stakeholders and talents both within and outside of our organization – our dedicated donors, staff, and volunteers; corporate, media, community, and industry partners; 300,000 Canadians with T1D and their families and friends; JDRF-funded researchers and their teams and institutions; government partners; and other like-minded charitable organizations. It is inspiring how many of us there are, all pulling together to defeat T1D.

In 2017, JDRF and its partners hit extraordinary new levels of collaboration – and success. With our many partners coming together to move forward, with a laser focus on our joint goal to defeat T1D, we saw some truly amazing results. For example, 2017 marked the launch of the landmark Partnership to Defeat Diabetes, our new, shared, $30 million investment with the Government of Canada (see p. 7), which will increase support for the best and brightest Canadian and international researchers working to accelerate T1D breakthroughs.

We also saw an unparalleled collaborative effort when many Canadian adults were faced with a sudden denial of the Disability Tax Credit, which had previously provided vital tax relief from the high health-care costs associated with T1D. After we joined forces with the T1D community and Diabetes Canada in a highly publicized advocacy campaign, we realized a big win – the interpretation that had disqualified adults with T1D from the credit was reversed (more on p. 13).

Of course medical research is always an impressive example of partnership, with each research team’s completed study building upon the knowledge that other teams have uncovered before them, and adding another block to scientists’ collective understanding of T1D. Leveraging the discoveries of the past, JDRF-funded researchers in 2017 were working on some of the most promising developments to date in the field, such as a dual-hormone artificial pancreas and new therapies to address dangerous levels of hypoglycemia (see p. 8).

JDRF Canada and its many partners also did so much more in 2017 to support Canadians living with T1D, and we invite you to learn about these accomplishments in this report. We are truly humbled by the passion and commitment of our generous donors, volunteers, and so many other partners, which makes all of this work possible.

By bringing everyone together in the fight for better treatments and a cure for T1D, we’ve always pulled together to go forward, faster. Thank you for putting your trust in us. Together, we are closer than ever to defeating this disease.

With gratitude,

Lorne Shiff
Chair of the Board
JDRF Canada

Dave Prowten
President & Chief Executive Officer
JDRF Canada

“With our many partners coming together to move forward, with a laser focus on our joint goal to defeat T1D, we saw some truly amazing results in 2017.”
RESEARCH UPDATE

Our Research

Type 1 diabetes (T1D) is an autoimmune disease in which a person’s pancreas stops producing insulin, a hormone people need to get energy from food. T1D strikes both children and adults, and its onset has nothing to do with diet or lifestyle. There is currently nothing you can do to prevent it, and there is no cure.

Research Program Areas

JDRF funds multiple therapeutic approaches to cure, prevent and treat T1D and its complications.

- **Artificial Pancreas**: Systems that can automatically deliver more effective and precise insulin and multi-hormone therapy.

- **Beta Cell Replacement**: Cell replacement therapies in a protective device that can provide long-term relief from insulin therapy without the need for intensive immune suppression.

- **Complications**: Therapies that prevent or better treat T1D-related damage such as eye and kidney disease.

- **Glucose Control**: Treatments that will improve the body’s glycemic balance through innovative and personalized therapies beyond the use of insulin alone.

- **Prevention**: Therapies that will keep individuals, especially those at higher risk, from ever developing T1D.

- **Restoration**: Stopping or reversing the autoimmune attack and restoring the body’s ability to produce insulin, which would represent a biological cure for T1D.

How JDRF Funds Research Globally

JDRF uses various funding mechanisms in order to build a diverse research portfolio, provide the research community with alternative approaches to address our mission and to provide research training opportunities that attract new talent to the field. Our portfolio is very dynamic, with the number of active grants changing as projects are launched and then completed.

Our research portfolio is overseen by internal and external experts who are responsible for ensuring scientific integrity and strategic direction.

Active JDRF Grants by Program Area

- **Transportfolio**: 3%
- **Artificial Pancreas**: 9%
- **Restoration**: 35%
- **Beta Cell Replacement**: 16%
- **Complications**: 7%
- **Prevention**: 21%
- **Glucose Control**: 9%
JDRF Active Grants in 2017

<table>
<thead>
<tr>
<th>TYPE OF FUNDING</th>
<th>DESCRIPTION</th>
<th>NUMBER OF ACTIVE GRANTS*</th>
</tr>
</thead>
<tbody>
<tr>
<td>STRATEGIC RESEARCH AGREEMENTS</td>
<td>Addresses critical gaps and challenges and potential breakthroughs in T1D research</td>
<td>309</td>
</tr>
<tr>
<td>TRAINING OPPORTUNITIES</td>
<td>Designed to attract the most promising scientists to the field of T1D research</td>
<td>94</td>
</tr>
<tr>
<td>INNOVATIVE GRANTS</td>
<td>Supports highly innovative research with significant potential to accelerate our mission</td>
<td>47</td>
</tr>
<tr>
<td>PARTNERSHIPS</td>
<td>Provides funding for T1D research in collaboration between JDRF and other nonprofits, government agencies or industry</td>
<td>33</td>
</tr>
<tr>
<td>INDUSTRY DISCOVERY &amp; DEVELOPMENT PARTNERSHIPS</td>
<td>Promotes private sector interest in JDRF’s mission by fostering long-term relationships with industry focused on T1D therapies</td>
<td>27</td>
</tr>
<tr>
<td>OTHER</td>
<td></td>
<td>6</td>
</tr>
<tr>
<td><strong>TOTAL</strong></td>
<td></td>
<td><strong>516</strong></td>
</tr>
</tbody>
</table>

*As of December 2017

T1D Research Development Pipeline

We identify and invest in promising global therapies in their early stages, helping researchers pursue innovative ideas and approaches. This investment strategy ensures that the most life-changing breakthroughs can make it through the long research, development and delivery process. As therapies progress into the later stages of development, JDRF leverages our industry partnerships to move therapies to market.

Pipeline Stages Defined

All new therapies progress through a series of stages before they reach the people who need them. Of the 516 international research grants JDRF funded during fiscal year 2017, 388 are tracked through the research pipeline. Training grants and innovative grants are among those not tracked by development stage.
Clinical Trials

Testing therapies in human clinical trials is a critical step to deliver innovative breakthroughs to our community. Not only are clinical trials a requirement for regulatory approval, we gain scientific understanding from these studies as we learn what’s safe and what works. JDRF supported more than 70 human clinical trials of drugs and devices internationally in fiscal year 2017. JDRF researchers track 57 of these trials by development phase. Other trials may be tracked by JDRF partners or are tracked outside of the traditional development pipeline.

### JDRF Clinical Trials Connection

You can be a part of the science by participating in a clinical trial. Visit the JDRF Clinical Trials Connection online to find trials that need volunteers.

[jdrf.org/research/clinical-trials](jdrf.org/research/clinical-trials)

<table>
<thead>
<tr>
<th>NUMBER OF TRIALS</th>
<th>PHASE I Proof of Concept</th>
<th>PHASE II Pilot</th>
<th>PHASE III Pivotal</th>
</tr>
</thead>
<tbody>
<tr>
<td>12</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>37</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>8</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>FOCUS</th>
<th>PHASE I Proof of Concept</th>
<th>PHASE II Pilot</th>
<th>PHASE III Pivotal</th>
</tr>
</thead>
<tbody>
<tr>
<td>Safety and dosage</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efficacy and side effects</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Efficacy compared to existing therapies</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>TYPICAL NUMBER OF PARTICIPANTS</th>
<th>PHASE I Proof of Concept</th>
<th>PHASE II Pilot</th>
<th>PHASE III Pivotal</th>
</tr>
</thead>
<tbody>
<tr>
<td>20 to 100 volunteers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Up to several hundred volunteers</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>100 to 3,000 volunteers</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

### POST-APPROVAL STAGE

As therapies progress into the later stages of development, JDRF leverages our industry partnerships to move therapies to market.

### Leading the Charge

**Leveraging Our Investments to Amplify Our Impact**

Moving potentially life-changing therapies from the laboratory to the real world requires enormous resources. The current cost to bring a product from discovery research through to commercial availability is estimated to exceed $1 billion USD. To help meet these needs, JDRF forms research funding partnerships that bring more dollars to the T1D research arena.

By partnering globally with academia, foundations, industry, governments, regulators, insurers, health-care providers and the T1D community globally, we can expand the pool of funding available to accomplish our important work and amplify our impact. In fiscal year 2017, JDRF attracted more than $214 million USD in funding from partners, bringing a total of $300 million USD to T1D research.
Forging Strategic Partnerships to Drive Research Forward

In the private sector, we collaborate internationally with industry partners, device manufacturers, innovative startups, technology firms and companies outside the T1D field to further our research goals. Partnering with industry is part of our strategic plan to deliver potentially transformative therapies into the hands of people with T1D.

**JDRF LEVERAGE**
For every $1 USD JDRF invests internationally in research, an additional $2.50 is brought into the field.

$300M USD to T1D research in 2017

- $114M NGO and Other Funding
- $166M Government Funding
- $36M Industry Partnerships
- $86M JDRF Direct Funding

JDRF attracted $214M in additional investments for T1D research

JDRF is the leading global organization funding T1D research

In fiscal year 2017, JDRF

- supported research in more than 18 countries
- invested more than $86 million USD in T1D research worldwide
- awarded 140 new research grants worldwide
- supported 38 Canadian researchers
- funded 70 international research projects with clinical trials for potential T1D therapies
Partnership to Defeat Diabetes

Landmark collaboration accelerates T1D research

In April 2017, the Government of Canada and JDRF announced an exciting new partnership to fast-track type 1 diabetes clinical research in Canada – which represents a significant investment benefitting more than 300,000 Canadians living with T1D.

Announced by David McGuinty, MP, on behalf of the Honourable Jane Philpott, then Minister of Health, the agreement was the culmination of several years of effort collaboratively undertaken by JDRF and members of Parliament’s All-Party Juvenile Diabetes Caucus.

As a result of the Partnership to Defeat Diabetes, the Government of Canada will work with JDRF through the Canadian Institutes of Health Research (CIHR), with each partner committing $15 million, for a total of $30 million. The Partnership will enhance Canada’s state-of-the-art leadership in funding the best and brightest in T1D research.

"CIHR is proud to be working with JDRF to support research on type 1 diabetes," said Dr. Philip Sherman, former Scientific Director of CIHR’s Institute of Nutrition, Metabolism and Diabetes. "This new partnership will focus the efforts of the diabetes research community in Canada and speed the development of new and better treatments for all Canadians with diabetes.”

Pamela Goldsmith-Jones, chair of the All-Party Juvenile Diabetes Caucus, has long been a strong advocate for the partnership. She is also the parent of a daughter with T1D. “As chair of, and on behalf of, the caucus, I salute JDRF and CIHR in their historic research Partnership. Our government listened. Our caucus worked across party lines so that type 1 will become type none.”

JDRF and CIHR’s first joint investment of $7.7 million will fund the following studies:

- **Dr. Rémi Rabasa-Lhoret from the Montreal Clinical Research Institute**, investigating how teens and adults can improve control of their blood glucose levels using an online educational program, and creating a new patient registry for preventing dangerous hypoglycemia.
- **Dr. Farid Mahmud from The Hospital for Sick Children**, looking at whether a new drug can help teens with T1D to improve control of blood glucose levels in the interest of preventing long-term kidney and heart issues.
- **Dr. Gillian Booth from St. Michael’s Hospital**, piloting a new way of treating people with T1D through frequent, brief visits with doctors via videoconferencing.
2017 Breakthroughs

JDRF’s research program saw a banner year of breakthroughs in 2017. Our many partners around the world – scientists and clinicians, research institutes, public sector organizations, and industry – all pulled together, united in our focus on achieving actionable discoveries to improve the lives of Canadians with T1D. Here are just a few of the year’s most exciting developments.

Encapsulation Update

Encapsulation is a process that involves implanting insulin-producing pancreatic beta cells into people with T1D, and then protecting those cells from immune system attacks – without the use of immunosuppressant drugs – so they can keep producing insulin. It is a promising field that could one day allow people to live their lives without needing insulin pumps or needles – essentially it means freedom from T1D.

Which is why in July 2017, the JDRF Encapsulation Consortium – a group of scientists from 25 institutions worldwide focused on encapsulation research – got together to discuss their latest JDRF-funded advancements. These include:

- A study led by McGill University chemical engineering professor Dr. Corinne Hoesli, who is using a 3D printer to create an encapsulation implant that will encourage the growth of capillaries to nourish and protect the beta cells inside it.
- Work by Dr. Mark Poznansky at Harvard University, who is looking at a protein called CXL 12 that repels destructive immune cells that destroy or damage implanted beta cells.
- Research by Dr. Timothy Kieffer and his team at the University of British Columbia, which is looking at the best combinations of cell types and transplantation methods to allow beta cells to survive and thrive post-transplantation.

Developing a New Treatment for Hypoglycemia

Hypoglycemia (low blood sugar) is a major source of fear for people with T1D, and for good reason; low blood sugar can be life threatening and increase the incidence of serious T1D complications. Now, Canadian preclinical life sciences company Zucara Therapeutics Inc. is developing a treatment that promises to change all that – through a new drug that can reduce incidences of hypoglycemia in people with T1D, particularly in cases where blood sugar might otherwise drop to dangerously low levels. The drug works by “turning on” the pancreas’s ability to counter-regulate hypoglycemia.

In 2017, JDRF announced it would contribute funding to help Zucara undertake the work necessary to prepare for clinical trials of the drug starting in 2019. The funding builds on JDRF’s previous support of the work of Dr. Michael Riddell of York University and Dr. Richard Liggins of The Centre for Drug Research and Development at the University of British Columbia, the founding scientists behind Zucara.
Advancing the Artificial Pancreas

An artificial pancreas is an externally placed device consisting of an insulin pump, a continuous glucose monitor, and a control algorithm that helps people with T1D to reach their target blood sugar range. Now JDRF-funded researcher Dr. Rémi Rabasa-Lhoret, an endocrinologist at the Montreal Clinical Research Institute, is going one step further, heading one of the first teams in the world working on a dual-hormone version of the device.

The current model of the artificial pancreas (available in the United States) is an insulin-only system. Though still in its infancy, the dual insulin-glucagon hormone system that Dr. Rabasa-Lhoret and his colleagues are developing has been observed in trials among adults and children to offer better glucose control and an additional “safety net” to deter low blood sugar. “We are examining the viability of a dual hormone system because we believe that hypoglycemia is harder to alleviate solely with current insulin,” explains Dr. Rabasa-Lhoret.

While the research shows great promise, there are still a number of factors to consider before this system is ready for regulatory approval. “We have no established timeline regarding the introduction of the artificial pancreas in Canada,” says Dr. Rabasa-Lhoret. “Glucagon is expensive and its potential benefits are still being studied. Also the approved artificial pancreas in the US is based on pumps not yet approved here.”

Using Machine Learning to Prevent T1D in Children

JDRF is collaborating with IBM on a large-scale research project to investigate the risk factors leading to the onset of T1D. Using previously collected data from JDRF-funded studies from around the world, IBM scientists are developing and applying machine learning algorithms, a type of artificial intelligence, to reveal patterns and factors at play, with the goal of identifying ways to delay or prevent T1D in children. “One of JDRF’s greatest strengths is our ability to engage both the public and private sector to accelerate T1D research,” says Dave Prowten, President and CEO of JDRF Canada. “This collaboration with IBM is a great example of our extraordinary global research program working together with a blue-chip global company to have a significant impact on the lives of children and families with T1D.”

In Memorium: Bob Goldstein

JDRF Canada celebrates the life of Dr. Robert (Bob) A. Goldstein, who passed away in early 2018. Bob’s impact on T1D research worldwide has been profound and will be long-lasting. In 1997, he joined JDRF International to lead our first in-house research team. In 2010, he became Chief Scientific Officer of JDRF Canada, where he was instrumental in developing the Canadian Clinical Trials Network. More recently, he played an integral role in establishing the Partnership to Defeat Diabetes with the Government of Canada. The T1D community owes Bob a significant debt of gratitude, and we will miss his wisdom, his piercing intelligence, and his abiding commitment to our mission.
Dr. Denice Feig and the CONCEPTT Trial

Study shows continuous glucose monitoring leads to better outcomes for newborns

Pregnant women with T1D experience more complications compared to those without it, affecting 50% of babies born to women with T1D. Complications include premature birth and higher-than-average birth weight, pre-eclampsia and Caesarean sections.

However, thanks to a recent JDRF-funded study, pregnant women with T1D are now armed with new knowledge to reduce the risk of these complications. The study, called “CONCEPTT: Continuous Glucose Monitoring in Women with Type 1 Diabetes in Pregnancy Trail,” revealed that monitoring a woman's blood sugar levels using a continuous glucose monitor (CGM) during pregnancy leads to better outcomes.

Dr. Denice Feig, the head of the Diabetes in Pregnancy Program at Mount Sinai Hospital and University Health Network in Toronto, is the co-principal investigator of the study. “For a long time, it has been difficult to change the fact that mothers with T1D and their babies have worse outcomes than those for the rest of the population,” she says. “But the CONCEPTT trial showed a significant new option to help pregnant women with type one diabetes and their children.”

Among the study’s specific findings was that expectant mothers who used a CGM spent an extra 100 minutes each day with blood sugar levels in the recommended range in late pregnancy. In addition, says Dr. Feig, “Our research showed that every six women using a real-time CGM device meant one fewer baby experiencing a hypoglycemic (low blood sugar) event. And for every eight women using the device, there was one less neonatal intensive care unit admission over 24 hours.”

CGM devices, which automatically monitor blood glucose levels at set intervals, improve diabetes management by allowing someone to take action immediately in response to high or low blood sugar levels.

The landmark randomized international trial was held across 31 hospitals, in Canada (11 sites across Alberta, Ontario, Quebec, and Nova Scotia), the United Kingdom, Spain, Ireland, Italy, and the United States, and involved 325 women ages 18 to 40.

The CONCEPTT study was funded by JDRF’s Canadian Clinical Trials Network, a partnership between JDRF Canada and FedDev Ontario, a Government of Canada agency.
GOVERNMENT RELATIONS AND ADVOCACY

When it comes to government relations and advocacy, the power of partnerships can be awe-inspiring. By bringing together Canadians with T1D, researchers, government representatives, and like-minded organizations, great things become possible (such as the landmark Partnership to Defeat Diabetes – see p. 7). Read on to learn more about the gains made by JDRF and our advocacy partners in 2017.

Manitoba Lobby Day

Insulin pumps have become an indispensable tool for many people with T1D, providing huge advances in glucose control. In Alberta, Ontario, Nunavut, Northwest Territories, and Yukon, the costs of insulin pumps are covered by provincial/territorial health plans. Not so in Manitoba, where only residents under 18 qualify for the current program – leaving adults with T1D to cover the $4000 - $6000 cost of a pump in other ways – if they are able to do so at all.

To address this barrier, on November 8, 2017, JDRF launched the “Insulin Pumps for All” campaign in Manitoba, as part of T1D Heroes Lobby Day and National Diabetes Awareness Month. Ten local Ambassadors living with T1D, supported by JDRF board and advocacy committee members, met in Winnipeg with 32 Manitoba Members of the Legislative Assembly (MLAs) to discuss how the lack of insulin pump coverage was affecting adults with type 1. Nearly all of the MLAs in the Legislature that day wore a blue ribbon to show support for people with diabetes. JDRF Canada has continued to meet with and lobby the Government of Manitoba and Manitoba Health, and we look forward to future discussions and a resolution on this issue.

Advocating for Kids with T1D at School

When a parent has a child with T1D, school comes with a special set of worries. Who will be responsible for a child’s daily T1D management, and how will they know what sort of care is needed? JDRF Canada is happy to report that in October 2017, Ontario’s Ministry of Education issued a new draft Policy Program Memorandum that required all school boards in the province to have board-level policies aimed at keeping students with diabetes (and other medical conditions) safer at school.

Ontario’s new draft policy came after JDRF met with ministry officials, organized letter writing and petitions, and contributed feedback alongside the Diabetes@School coalition and parent advocates. The coalition, led by Diabetes Canada, the Canadian Paediatric Society, and the Canadian Pediatric Endocrine Group, is calling for province-wide policies that address the day-to-day management of diabetes in schools. Currently, Alberta, Saskatchewan, Manitoba, PEI and Canada’s three territories still lack province-wide policies on diabetes in schools.
Rallying for the Disability Tax Credit

In mid-2017, many Canadians with T1D who had previously been approved for the federal Disability Tax Credit (DTC) suddenly began hearing they were being denied the credit.

The change was a result of a controversial new tax directive introduced by the Canada Revenue Agency (CRA) that made it virtually impossible for adults with T1D to qualify for the DTC. Worth about $1500 on average annually, the DTC had provided many Canadians with T1D a small measure of tax relief against the considerable health costs of the disease, which can sometimes run upwards of $15,000/year. Since the DTC is also tied to Registered Disability Savings Plans, CRA’s actions also put at risk any hard-earned savings Canadians with T1D had invested in them.

After hearing multiple reports of denied claims, it was time for action. So in November, JDRF Canada, Diabetes Canada, and the T1D community across the country came together in a campaign to demand that the new interpretation be rescinded. JDRF’s advocacy committee spread the word through social media and other channels, and as a result, Canadians with T1D swung into action, in a massive display of grassroots advocacy, sending more than 1600 letters to their MPs and Canada’s Finance Minister through our campaign. They also shared their stories widely on social media (the greatest engagement ever on JDRF’s social media channels) and made phone calls and met with their MPs, resulting in a number of tough questions in the House of Commons.

Meanwhile, JDRF and Diabetes Canada also attended meetings in Ottawa with the Minister of National Revenue and the CRA, and with medical experts from the Canadian Medical Association and other organizations. On December 4, JDRF and Diabetes Canada held a joint news conference that resulted in a tremendous amount of media coverage – all of Canada was now hearing about the impact of the change on the T1D community! JDRF President and CEO Dave Prowten even did a Facebook Live video on Parliament Hill, which has been seen 13,500 times.

On December 8, the Government of Canada and CRA announced they would rescind the interpretation, making it possible for adults with T1D to qualify for the DTC again. Since then, nearly everyone who has had their claim evaluated has received the tax credit (although some are still awaiting the results of their claim).

Thank you to all of our volunteer advocates who made this possible in 2017 – your efforts truly demonstrated the power of advocacy to change people’s lives!

We invite you to become a JDRF Advocate! Lend your voice to help advocate for policy change and make a big impact for those living with T1D. It’s easy and doesn’t take a lot of time. You can sign up at jdrf.ca/advocate
IN OUR LIFETIME CAMPAIGN

In Our Lifetime is a promise – a commitment from researchers, major donors, and other leadership partners – to keep moving the research agenda forward towards the breakthroughs that will transform the lives of Canadians with T1D. Thanks to your support, we are getting there.

The campaign has raised $26 million to date

IN OUR LIFETIME CAMPAIGN:
Peter Oliver, Chair
The Right Honourable Brian Mulroney, Honourary Chair

Campaign Update

In 2017, JDRF had another successful year of major gift fundraising towards the In Our Lifetime Campaign. The campaign aims to capitalize on the exciting promise that current research offers to – in our lifetime – cure or treat T1D so effectively that people will live as if they don’t have T1D at all. The campaign has raised $26 million to date, with widespread support and amazing volunteer cabinet leadership from across the country. And with the Government of Canada’s $15 million matching gift through the Partnership to Defeat Diabetes (see p. 7 for more information), JDRF looks forward to working with our generous donors to leverage this opportunity throughout 2018. For more information, please contact Susan Delisle, Vice President, Philanthropy and Corporate Partnerships, at 1-877-287-3533 ext. 2324 or sdelisle@jdrf.ca.

The Beta Society

JDRF’s Beta Society honours visionary individuals who have made a lasting commitment to JDRF to help provide the present and future financial support needed for T1D research. Beta Society members are those who have made a planned gift to JDRF – such as through their Will, a gift of life insurance, or a charitable bequest – which is arranged during their lifetime but made available in the future. Planned giving allows donors to leave a substantial legacy for T1D research while providing them with significant tax benefits.

To become a Beta Society member, you simply need to include JDRF in your estate plans and let us know. Your involvement may also inspire generosity in others! With your membership, you will receive regular updates and invitations to special events. For more information, please contact Caroline Lewis, National Manager of Planned Giving, at 1-877-287-3533 ext. 2044 or clewis@jdrf.ca.
A Family Disease, and a Family Legacy

Spotlight on the Gaglardi Family

When Wilson Gaglardi was six, he was diagnosed with T1D.
“I didn’t know what it was, and I thought it wasn’t a big deal, he says. “I was young, and I didn’t know it would change my life.”

Today Wilson is 12, and T1D has definitely changed his life – and then some.

“It really was a shock,” says his father Tom Gaglardi, president of the Northland Properties Corporation and owner of the Dallas Stars. “I’ll never forget sitting in the hospital after Wilson was diagnosed, with the doctors outlining, over a couple of hours, exactly what was involved with type 1. It was life-changing for sure, for all of us – it is a family disease.”

Every night, Tom and his wife Brittney get up three or four times to wake Wilson and check his blood sugar. Wilson also checks himself multiple times during the day. For years, they’ve dealt with pumps, needles, and the inevitable highs and lows. Sometimes Wilson tells his dad he’s tired, and wishes he didn’t have type 1 anymore. “T1D is extremely tough, and no one should have to go through it,” says Tom. “We need to find a cure.”

Which is why, in 2017, the Gaglardi family – Tom, Brittney, Wilson, and their two other sons, Charlie and Bennett – made a $3 million gift to JDRF Canada’s In Our Lifetime Campaign, in support of research in encapsulation and beta cell replacement and regeneration.

“The research has progressed so much already, and the Gaglardi Family’s extraordinary gift will bring us even closer to a cure,” says Dave Prowten, president and CEO of JDRF Canada. “On behalf of everyone whose life is affected by TID, we thank them.”

More than 50 scientists worldwide are currently involved in JDRF’s encapsulation consortium. They are developing ways to generate beta cells, creating bioengineered protective barriers and devices that can be implanted in people with T1D, and shielding beta cells from immune system attack.

“Our family is incredibly proud to support JDRF in funding this critical research. I’m very impressed with the level of professionalism and care that JDRF takes when it’s managing donors’ money.”
- TOM GAGLARDI
MEET OUR VOLUNTEERS

JDRF relies on the dedication and support of thousands of volunteers to pursue our mission. These individuals, families, and corporate teams come from diverse backgrounds, bringing a wide range of skills and experience. Here is a look at just a few of them – and how they are some of our most critical partners in turning type one into type none! jdrf.ca/volunteer

Approximately 7,500 incredible volunteers across Canada help drive JDRF’s mission

Ally Gasco

Ally Gasco of Burlington, ON, has a very personal reason for volunteering as a JDRF Mentor. The mother of two was diagnosed with T1D at age 12, and remembers well the shock she felt when her daughter Kira was also diagnosed at almost the same age. “That feeling tightened its grasp on my heart. At that moment, I would have done anything to keep my daughter from her diagnosis.” Today, Ally has come to acceptance, and her daughter is handling things with “grace and inner strength,” she says. The mentor program allows Ally to put her hard-won experience to good use – now she provides peer support for other parents of newly diagnosed children.

Mike LeBlanc

In 2017, volunteer extraordinaire Mike LeBlanc of Dieppe, NB, celebrated the 10th anniversary of Mike’s Bike Shop Cyclebetes, which has raised $200,000 for JDRF to date. An avid cyclist, Mike brought together several competitive cycling friends and bike shop owner Rick Snyder in 2007 to create the yearly fundraising event, inspired by his daughter Adèle, who has T1D. In 2017, 75 energetic participants rode in Cyclebetes’ 45 km, 75 km and 125 km rides – some even did both of the 75 km and 125 km rides – to cycle 200 km for a cure!

Loree Felt and SunRype

Loree Felt (whose daughter and son both have TID) and her team at SunRype Products Ltd. in Kelowna, BC, are exceptionally energetic volunteers in the Sun Life Walk to Cure Diabetes for JDRF, contributing between 100 to 150 hours to the event every year. In addition to the support SunRype provides as a national Walk supplier, SunRype staff fundraises for their Walk team, the Apple Crushers, all year round; that dedication really paid off in 2017 when they became the top fundraising team in Kelowna! To date, SunRype and its employees have contributed more than $1.8 million in cash and in-kind donations since becoming involved in the Walk in 2004.

Members of the SunRype team: (left to right) Jane Williams, Sarah Desharnais, Cory Lyn Boden, Loree Felt, Barbara Adams
JDRF IN THE COMMUNITY

Hope for Newly Diagnosed Families

The Bag of Hope program provides critical support and information to families when they need it most—while coping with a new T1D diagnosis. In 2017, more than 1,500 families received Bags of Hope through diabetes education centres across the country. Each kit comes full of helpful information and resources, and for those under 12, the bag also contains Rufus, the Bear with Diabetes,™ to help children learn about insulin injections.

Boston Pizza Youth Ambassadors

Each year, many youth in Canada cope with the diagnosis of T1D. The JDRF Youth Ambassador Program, supported by Boston Pizza Foundation Future Prospects,™ empowers young people with T1D each year by providing them with opportunities to develop their leadership skills, connect with other youth leaders living with T1D, and share their voices to benefit JDRF’s research and the T1D community. In 2017, our 300 Youth Ambassadors were very busy! Here are just some of their contributions:

• Attended 23 training sessions to prepare for their roles
• Made more than 7,500 thank you calls
• Spoke at 84 Walk, Ride, and Gala events
• Made more than 3,700 community appearances and shared their personal stories in meetings with government officials and the media

A Trusted Mentor

JDRF’s mentor program provides one-on-one support to families and individuals living with T1D. Trained volunteers who understand the daily challenges of T1D provide people who are newly diagnosed with vital emotional support, connections to local resources, and answers to questions based on their own experience. In 2017, the program matched 1,100 individuals (adults with T1D or the parents of diagnosed children) with a caring volunteer mentor.
OUR EVENTS

In 2017, JDRF events saw many individuals and organizations joining together to defeat T1D, including our annual Walk and Ride signature fundraising events, National Diabetes Awareness Month (NDAM), our many fabulous JDRF galas, and creative and fun community fundraising events conceived and run by our supporters.

Ride

The JDRF Revolution Ride to Defeat Diabetes, presented by Sun Life Financial, is a high-energy cycling event taking place in cities across Canada. In 2017 our amazing Ride “Revolutionaries” raised more than $3.5 million through the event! They rode in pumped up stationary cycling challenges, sweated it out in “virtual” rides of their own design, and even took part in long-distance destination iRides in some of North America’s most spectacular locations. A special thank you to our top fundraisers nationwide: David Kozloff, Louis-Philippe Thibodeau, Peter Heffernan, Lorne Shiff, Vanessa Oliver, Kristy Hoffman, Steve Ichelson, Michael Sutherland, Samantha Sutherland, and Mike Archibald. jdrfrevolution.ca

Spotlight: Scotiabank

What a team: In 2017, Scotiabank was the top Canadian corporate supporter for the JDRF Revolution Ride to Defeat Diabetes, presented by Sun Life Financial, raising $500,000 to advance T1D research with almost 2,500 Scotiabank Revolutionaries riding! With leadership by Graham Anderson at Scotiabank Toronto, who rallied support across the organization, the campaign grew by 25% over the previous year, fuelled by the hard work and passion of Scotiabank employees across the country. Special shout out to Angie Watson and her crew for being the top fundraising corporation in Regina in 2017 (and six years previously). Angie herself has volunteered countless hours chairing the Regina Ride cabinet and growing the event into what it is today.
Walk

In 2017, more than 40,000 walkers in 68 communities across Canada came together for the JDRF Walk to Cure Diabetes, united as one to raise **$5.6 million** for T1D research! We also celebrated **TELUS**’ 10-year milestone as the title sponsor of the Walk, during which time the company and its amazing employees raised $10 million. The 2017 Walk saw the introduction of our popular new Walk with a Researcher program, which provides participants in Toronto, Montreal, Calgary, Edmonton and Vancouver who raise $5K or more the opportunity to walk 5 km alongside a JDRF-funded scientist to learn about some of the latest developments in T1D research. A special thank-you to our top fundraisers nationwide: Sharan Narang, Alisha Armour, Jack Stuart, Kristy Hoffmann, Michael Milloy, Jaya and Ed Hiutin, Brian Horlick, Suzanne Reisler Litwin, and Scott Totten.

In 2018, the event’s 25th anniversary, we warmly welcome Sun Life as our new title sponsor for our Walk, now known as the **Sun Life Walk to Cure Diabetes for JDRF**. jdrfwalk.ca

---

**Spotlight: Ford Windsor**

In 2017, employees at the **Ford Windsor Walk team** (Ford Windsor Site; UNIFOR Locals 200, 240, and 444; and local Ford Windsor dealers) hit an impressive milestone – **$1 million raised cumulatively** since they began fundraising for JDRF’s Walk to Cure Diabetes in 2002! The team is “tireless,” says JDRF’s Nicole Cozad, raising money for its Walk effort year-round through golf tournaments, car washes, barbecues, bowling nights, and much more. “Nothing makes me happier than when someone who has a family member with type 1 comes up to say thanks for what our team has done,” says Mario Hindi, who chaired Ford Windsor’s Walk committee from 2003 – 2017. “I have always felt that we should work for the cause and not for the applause.”
National Diabetes Awareness Month

In November 2017, we celebrated National Diabetes Awareness Month (NDAM) along with the global T1D community. NDAM provides a huge annual opportunity to raise greater public awareness about T1D, and our supporters across the country swung into action to help. The awareness campaign also raised significant funds for research, thanks to a donation match offered by the Gameroff family from Montreal, QC.; the family was motivated to offer the match thanks to the Partnership to Defeat Diabetes. “We felt it particularly important because we saw that if we could offer to match donations made by other families to JDRF, the federal government would double them, meaning the funds will actually be quadrupled,” said David Gameroff, whose son Matthew has T1D.

Other highlights from NDAM included:

• #T1D Loud – where people with T1D shared their stories in online videos
• Our popular Mythbuster ad campaign – designed to dispel common misconceptions about T1D
• Manitoba Lobby Day (see p. 12)
• Extensive media coverage, which resulted in a combined audience reach of about 3 million, and a number of cross-country high-visibility digital billboards featuring the Gameroff family and others, including at Yonge-Dundas Square in Toronto
• A Facebook Live event on the topic of “Exercise and T1D” hosted by Dr. Michael Riddell (a JDRF-funded researcher who lives with T1D) in his exercise physiology lab at York University, which was seen by over 9,200 viewers internationally.

Galas for a Cure

In 2017 more than 4,000 guests attended JDRF galas in 10 cities, raising $3.9 million for T1D research. Highlights included the “A Starry, Starry Night” gala in Winnipeg, which celebrated its 30th anniversary (and raised a record-setting $640,000), and the Toronto “Night of Promise,” which saw an impressive 40% increase in donations from the previous year. As usual, guests at each event danced the night away, celebrated recent milestones in T1D research, and enjoyed the ever-popular Fund-a-Cure. Thanks to all of our gala volunteers and supporters for making these events such a resounding success. jdrf.ca/gala
Community Events

Each year, in communities across Canada, many groups and individuals create their own events in support of JDRF. From organizing golf tournaments, runs, and bowl-a-thons to bake sales and birthday celebrations, these wonderfully resourceful people are taking the initiative and raising significant funds for T1D research. We thank them!

Teed Up for T1D

Tony Amato, partner at the construction firm Pentian Group in Quebec, and father of Anthony, winner of JDRF’s 2016 Boston Pizza Youth Ambassador of the Year award, has been raising money for JDRF since 2008 through Pentian’s annual golf tournament. So far the always-sold-out tournament has contributed $250,000 to JDRF to help fund research - and find a cure - for T1D. The Amato family is also involved with JDRF in a number of other ways, from attending the Montreal DIA-BEAT-IT Gala to fundraising for the Walk and Ride.


Ron Hozjan of Calgary, AB, had an innovative idea for an event benefitting JDRF in 2017 – involving oysters! The CFO of Tamarack Valley Energy became an “honorary shucker” - pitted against a group of fellow shuckers in friendly competition – in the Macquarie Capital Markets Canada Ltd. annual Shuck Off and Seafood Feast. The event featured delicious seafood, rocking entertainment - and, best of all, raised nearly $70,000 for T1D research, thanks to Ron and his donors.

Would you like to host your own event or personal campaign for JDRF Canada to support our mission to cure T1D and improve the lives of those living with the disease?

Visit our Fundraise Your Way site to learn more: jdrf.ca/yourway
JDRF Canada would like to express its sincere gratitude to all of our corporate partners, whose support benefits children and adults with T1D across Canada through research that is leading to groundbreaking new treatments and a cure.

Thanks to the awareness you raise in communities across Canada, your financial support, and your heartfelt commitment, you bring hope every day to more than 300,000 Canadians and their families with TID.

jdrf.ca/our-supporters
JDRF CANADA BOARD OF DIRECTORS 2017

Lorne Shiff, Chair of the Board  
(Toronto, ON)

Dr. David Kozloff, Secretary  
(Montreal, QC)

Ron Miller, Treasurer  
(Calgary, AB)

Matt Varey, Past Chair  
(Toronto, ON)

Ashit Dattani  
(Vancouver, BC)

Sean Murray  
(Pictou, NS)

Aubrey Baillie  
(Toronto, ON)

Maarika Paul  
(Montreal, QC)

Mary Jane Devine  
(Vancouver, BC)

Ryan Shay  
(Calgary, AB)

Rita Hildahl  
(Winnipeg, MB)

Réjean Tremblay  
(Montreal, QC)

Judy M. Hunt  
(Villanova, PA)

Murray Suey  
(Calgary, AB)

Garth Lancaster  
(Winnipeg, MB)

Andrew Wilkin  
(Kitchener, ON)

Barbara Mendelsohn  
(Toronto, ON)

Scott Williams  
(Oakville, ON)